Hikma Pharmaceuticals PLC
Research Hikma Pharmaceuticals PLC (H5P) on Bullrun: market cap EUR 3.69B, P/E 11.1, dividend yield 4.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerH5P
- ExchangeF
- CountryUnited Kingdom
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 3.69B
- P/E11.1
- Dividend yield4.2%
- Financial periodFY2025
- RevenueEUR 3.35B
- Revenue growth7.1%
- Net incomeEUR 402.00M
- Free cash flowEUR 119.00M
- Gross margin43.0%
Valuation Snapshot
latest market cap is EUR 3.69B; P/E is 11.1; dividend yield is 4.2%.
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets.
Frequently asked questions
What is Hikma Pharmaceuticals PLC's market cap?
Hikma Pharmaceuticals PLC's market capitalization is EUR 3.69B.
What is Hikma Pharmaceuticals PLC's P/E ratio?
Hikma Pharmaceuticals PLC's price-to-earnings (P/E) ratio is 11.1.
Does Hikma Pharmaceuticals PLC pay a dividend?
Hikma Pharmaceuticals PLC has a dividend yield of 4.2%.
What does Hikma Pharmaceuticals PLC do?
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded.